Dementia care facilities would have to meet new state standards under WA bill
(Getty Images)
Washington lawmakers are looking at requiring assisted living facilities to be certified to take care of people with dementia.
Senate Bill 5337, sponsored by Sen. Tina Orwall, D-Des Moines, would require the Department of Social and Health Services to create, manage and enforce a certification process for licensed assisted living facilities.
'This bill is around supporting people as they age and supporting families and giving the Department of Social and Health Services the tools they need for that work,' Orwall said.
In 2021, an informal study by the state's Dementia Action Collaborative found there were about 237 assisted living facilities in Washington that advertised memory care or specialized dementia care, but their services varied.
'Currently there are about 126,000 seniors in Washington with Alzheimer's disease, which is about 10% of the population 65 and up and that number is growing every day,' said Brad Forbes from the Alzheimer's Association.
The lack of standardized care can make it difficult for individuals or families to understand the services and staffing that facilities offer.
'The challenge exists when the individual gives their trust and significant payments, sometimes $10,000 a month, for what they think is comprehensive care designed for a person experiencing cognitive decline,' said Joanna Grist, a lobbyist for AARP.
The bill would require these facilities to maintain staff onsite 24 hours a day, to have at least six hours of continuing education for workers per year related to dementia-related behaviors such as aggression, and provide to patients with individual and group activities.
A memory care facility is defined as one that is devoted specifically to that type of care or that offers a special unit or wing for those with dementia. They help people with housekeeping, meals, snacks, laundry and activities.
Under the bill, the department would have to maintain a publicly available list of certified assisted living facilities that specialize in memory care or have memory care units. They would also review facilities' compliance with state law and conduct regular inspections. Facilities that are out of compliance could face civil penalties.
The Senate passed the bill 49-0 last month, and it's now moving along in the House. If approved, the bill would require assisted living facilities to be certified by July 1, 2026.
'As we age, we want everyone to get the care they need and deserve,' Orwall said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
28bio Announces Nexon™ Neurotechnology Platform Powered by Engineered Human Brains
Exhibits complex neurological processes—including memory, learning, and cognition—and predicts human outcomes in preclinical drug development NEW ORLEANS, June 9, 2025 /PRNewswire/ -- 28bio today announced the Nexon™ neurotechnology platform—a major advancement in understanding human brain function. The platform integrates tissue engineering, neural interfacing and AI to engineer human brains at-scale and replicate complex neurological processes. The Nexon™ platform is now being used to improve the prediction of therapeutic efficacy and toxicity in humans, with several of the world's largest pharma companies already integrating Nexon™ into their drug development workflows. The Nexon™ platform also incorporates Organoid Intelligence (OI). The growing field of OI combines human brain organoids with brain-machine interfaces to model memory, learning, and cognition in vitro, offering novel functional cognitive biomarkers with the potential to reshape drug development in neurodegenerative disorders including Alzheimer's disease. Neurological drug development faces some of the highest failure rates in the pharmaceutical industry, due to poor translatability of animal models. Despite promising preclinical study results, many therapies ultimately fail in humans—contributing to a growing neurological health crisis and need for more predictive, human-relevant models. "We engineer human brains capable of elucidating the complexity of neurological processes and produce predictive data needed to change the trajectory of neurological drug development," said Alif Saleh, CEO of 28bio. "Industry and regulators are urgently asking for solutions to develop better neurological drugs faster and cheaper." About 28bio28bio is a neurotechnology company engineering human brains at-scale exhibiting memory, learning, and cognitive functions. Its Nexon™ platform integrates tissue engineering, neural interfacing, and AI to reverse today's neurological health crisis by improving the ability to predict which therapies will work in humans. 28bio is committed to advancing ethical standards in the development of brain organoid technology and engineered human cognition. For more information, visit View original content to download multimedia: SOURCE 28bio Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
a day ago
- Yahoo
FDA clears first blood test to help diagnose Alzheimer's disease
The test is for those aged 55 and older who are already exhibiting signs and symptoms of Alzheimer's disease.
San Francisco Chronicle
a day ago
- San Francisco Chronicle
New Alzheimer's blood tests make diagnosis easier — but they're not right for everyone
The number of Americans with Alzheimer's disease, the most common cause of dementia in the U.S., is projected to rise significantly in the coming decades. The devastating disease has no cure, but the past several years have brought promising developments in new drug therapies and blood tests that help doctors treat and diagnose the disease. Here's what to know about the blood tests that diagnose Alzheimer's, one of which got full FDA approval in May. How they work Several commercially available blood tests have become available the past few years, most recently from biotech company Fujirebio Diagnostics, which got full approval from the FDA last month. Each test measures slightly different things, but overall they look for abnormal levels of certain proteins — amyloid and tau — in the blood. The accumulation of amyloid and tau proteins in the brain, often called plaques, are hallmark signs of Alzheimer's. If someone has tau plaques in the brain, for instance, some of that will leak out of the brain into the blood, resulting in a blood test result showing higher than normal levels of tau. In patients with symptoms of cognitive impairment, the tests predict an Alzheimer's diagnosis with about 90% accuracy. Why they're important The blood tests are a notable development because they are less expensive and less invasive than other types of testing that doctors have long used to diagnose patients with Alzheimer's. One is a PET scan, which involves injecting a patient with a radioactive tracer that binds to amyloid or tau in the brain so the presence of the proteins can be seen in a scan. It can cost several thousand dollars, compared to several hundred dollars for a blood test. The other is a spinal tap, which is painful or uncomfortable for many people. This method measures different forms of amyloid and tau in the spinal fluid. 'Up until these blood tests came out, a physician was stuck doing a PET scan or spinal tap, so not great options,' said Dr. Frank Longo, a professor of neurology at Stanford Medicine. 'The big breakthrough is finding something to measure in the blood that's about 90% accurate of what's going on in the brain, about as accurate as spinal fluid or a PET scan.' Doctors use the blood test as part of a broader medical evaluation that also includes a patient history, neurological exam and other testing. The blood test can help rule out Alzheimer's as the cause of a patient's cognitive impairment and potentially avoid unnecessary further testing. If someone's blood test comes back normal, for example, they may not have to undergo the PET scan or spinal tap, and their doctor can look into other potential causes of the cognitive impairment. 'That's the biggest practical thing it's doing now,' Longo said. It's important to distinguish Alzheimer's from other types of dementia because there are Alzheimer's treatments that have come out the last few years that help slow the progression of Alzheimer's. But patients must be in relatively early stages of the disease, with mild impairment or mild dementia, to be eligible. Some of the therapies have significant side effects, so patients would not want to start them unless they knew it was Alzheimer's, and not something else, causing the dementia. They're not for everyone The tests are approved only for people who already have symptoms of cognitive impairment and are of a certain age — 55 and over or 60 and over, depending on the test. They are not approved for healthy adults with normal cognition who want to diagnose or rule out Alzheimer's, or who are simply curious if they are at risk for developing Alzheimer's. They must be ordered by a doctor. They're becoming more common, but may not be covered by insurance Some of the blood tests have been available for a year or two, Longo said, but they were under an earlier and more limited type of FDA approval, not the full approval that the agency granted last month to the Fujirebio test. So they are poised to become more common. 'A year ago, most of my colleagues and I were not ordering these,' Longo said. 'I'd say less than 5% or 10% of the time we were ordering these. Now people are starting to order them in symptomatic patients. It's not rare now. They're starting to be recognized more.' Some primary care doctors are starting to order the tests as well, said Dr. Armen Moughamian, medical director of Sutter Health's Ray Dolby Brain Center at CPMC in San Francisco. The center treats patients with memory disorders. 'It's definitely a minority, but I've been seeing it done,' he said. As with many new medical tests, insurers may not cover them yet, but that usually evolves over time. Full FDA approval may help make the case for the tests to be covered, Longo said. 'There is some uncertainty and lack of clarity about whether insurance and Medicare pay,' Moughamian said. 'That creates some hesitancy for providers to order it.' They may one day be used to screen and diagnose healthy people earlier In people with Alzheimer's, amyloid plaques begin to form in the brain as many as 20 years before they show symptoms. Right now, newer therapies for Alzheimer's — like lecanemab and donanemab, which slow the progression of the disease — are approved only for people with symptoms. Those symptoms are mild cognitive impairment or mild dementia, the early stages of symptomatic Alzheimer's. This means people who have not yet developed symptoms, but who have amyloid plaques in the brain, cannot get these treatments. So if a blood test could be used in pre-symptomatic people, it could mean better screening and earlier diagnosis to larger groups of people. 'What we want to push for is earlier diagnosis because new therapies are available when we catch people in earlier stages,' Moughamian said. Moughamian is leading two clinical trials that examine whether drugs that remove amyloid in the brain, donanemab and another drug remternetug, can work in people who have amyloid plaques but have not yet developed symptoms. They are using an Alzheimer's blood test to see whether patients are eligible for the trial.
